Fig 2: FACS analyses of FAMIN expression in PBMCs and granulocytes.PBMCs and granulocytes from human healthy donors were co-stained for different cell markers and FAMIN. Neutrophils, monocytes and DCs were shown to be FAMIN+. The events in the displayed graphs were first identified and gated by forward and side scatter parameters. (A) Gating strategy for FAMIN+ monocytes (CD14+, black) and CD14- neutrophils (CD15+, purple and CD16+, orange). (B) Gating strategy for FAMIN+ myeloid DCs (CD11c+, brown) and plasmacytoid DCs (BDCA2+, green) was obtained from gating the CD3-CD19- population followed by gating of CD14-HLADR+ cells. (C) Gating strategy for FAMIN+ T-cells (CD3+, purple) and B-cells (CD19+, orange). Numbers in the outlined areas indicate percent cells in each cell subtype. Data are representative of three independent experiments.

Fig 3: Effect of PPAR agonists FAMIN expression in THP-1 cells.WB analysis of FAMIN expression in THP-1 macrophages after 24hrs treatment with PPARa (WY14643) or PPAR? (rosiglitazone) as indicated. ß-actin were used as a loading control. Relative intensity (RI) from densitometric analysis is reported. Data are representative of three independent experiments. Abbreviation; UN: unstimulated control.

Fig 4: Analysis of human recombinant FAMIN laccase activity.Four phenolic substrates (DMP, Guaiacol, L-DOPA and SGZ) were tested in order to evaluate laccase activity of the C-terminal MYC/DDK-tagged recombinant FAMIN protein, as indicated. Data are representative of three independent experiments.

Fig 5: LACC1 mRNA expression in immune-related and gastrointestinal human tissues.(A) qRT-PCR analysis of LACC1 relative expression in a panel of human tissues identifies spleen and lymph nodes as tissues with higher LACC1 expression. Reactions were done in triplicates. (B) LACC1 mRNA expression data extracted from Genevisible (https://genevestigator.com/gv/).